Recent data presented at CROI 2021 provide insights on the clinical significance of INSTIs and weight gain. Here are my takeaways regarding cardiovascular and metabolic implications of INSTI-associated weight gain.
Healthcare professionals need better understanding of the processes involved with weight gain in patients taking antiretroviral therapy. New and upcoming data are providing valuable insights.
Recent trials of switch strategies involving 2-drug regimens aim to maintain strong virologic suppression while minimizing adverse events and maximizing tolerability. Here’s my take.
As our patients with HIV achieve longer life expectancies, the potential for drug–drug interactions increases as non-HIV–associated comorbid conditions arise.
Watch this dynamic faculty discussion on the impact of emerging ART safety and tolerability data on ART initiation and switch strategies.
Gain expert insight on the impact of emerging ART safety and tolerability data on ART initiation and switch strategies.
Review expert discussion on how new data from IAS 2021 expand our understanding of the adverse event profiles of specific ART regimens, with particular focus on weight, BMI, insulin resistance, and other metabolic parameters.
Review downloadable slides on adverse events associated with current and emerging ART regimens.
Gain expert insight on new data from fall 2021 HIV conferences that expand our understanding of adverse events associated with ART, with particular emphasis on weight gain, metabolic complications, and pregnancy.
Review downloadable slides on safety of ART regimens, including recent data on weight gain, metabolic complications, and pregnancy.
Hear insights and answers to audience questions from Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, on HIV ART safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs.
Hear insights and answers to audience questions from Fidelia Bernice, PharmD, and Aadia I. Rana, MD, on HIV ART safety and tolerability including recent data on nephrotoxicity and safety with long-acting injectables.